{"id":31392,"date":"2026-05-05T12:00:00","date_gmt":"2026-05-05T17:00:00","guid":{"rendered":"https:\/\/uwm.edu\/letters-science\/?p=31392"},"modified":"2026-05-05T22:09:38","modified_gmt":"2026-05-06T03:09:38","slug":"chemistry-researchers-start-up-takes-aim-at-triple-negative-breast-cancer-without-chemo-side-effects","status":"publish","type":"post","link":"https:\/\/uwm.edu\/letters-science\/in-focus\/research-news\/chemistry-researchers-start-up-takes-aim-at-triple-negative-breast-cancer-without-chemo-side-effects\/","title":{"rendered":"Chemistry researchers\u2019 start-up takes aim at triple-negative breast cancer \u2013 without chemo side effects"},"content":{"rendered":"\n

Triple negative breast cancer (TNBC) is one of the most aggressive forms of breast cancer, and it does not respond to any of the hormone therapies designed to treat other types of breast cancer. Instead, the first line of defense for patients with TNBC is chemotherapy with drugs like Paclitaxel or Carboplatin. These medicines do kill cancer cells, but they also attack healthy tissues, leaving patients with side effects that can range from unpleasant to debilitating.<\/p>\n\n\n\n

A new start-up founded by two UWM researchers is trying to change that.<\/p>\n\n\n\n

SynXT Therapeutics<\/a> was established last year by Dr. Xiaohua Peng, a UWM Professor of Chemistry & Biochemistry, and her former graduate student, Dr. Taufeeque Ali (\u201924, PhD Chemistry & Biochemistry). The company is developing a new type of cancer therapy that has shown great promise in treating TNBC without the nasty side effects of traditional chemotherapy.<\/p>\n\n\n\n

Ali and Peng founded their start-up with financial backing from several state agencies, as well as support from two Bridge Grants<\/a> awarded by the UWM Research Foundation<\/a>. They were just awarded their second Bridge Grant<\/a> in March.<\/p>\n\n\n\n

A novel treatment<\/strong><\/h2>\n\n\n\n
\"An
Xiaohua Peng is the Chief Scientific Officer of SynXT Therapeutics, Inc.<\/figcaption><\/figure>\n\n\n\n

Since she joined UWM\u2019s faculty more than a decade ago, Peng has been devoted to developing anti-cancer drugs with selectivity, meaning that these drugs would only target cancer cells with no toxicity for healthy cells.<\/p>\n\n\n\n

\u201cAfter 15 years of hard work, we identified a pro-drug which is highly promising, showing strong selectivity and very good efficacy in mouse studies,\u201d Peng said. \u201cWe designed compounds \u2026 which are not toxic, but they can be selectively, specifically, activated in tumor cells. They are toxic only to tumor cells.\u201d<\/p>\n\n\n\n

A \u201cpro-drug\u201d is a drug that remains inactive unless it comes into contact with an activating agent. In this case, said Ali, the activating agent is chemicals known as Reactive Oxygen Species, or ROS. ROS chemicals are byproducts of cellular metabolism, and cancer cells typically have higher levels of ROS than healthy cells. The pro-drug is a DNA alkylating agent, meaning it destroys DNA; in this case, the DNA of the cancer cells.<\/p>\n\n\n\n

What makes SynXT Therapeutics\u2019 pro-drug so novel, though, is that Peng and Ali have combined it with Vitamin C \u2013 yes, the same Vitamin C found in oranges and lemons. Vitamin C can spur the generation of ROS.<\/p>\n\n\n\n

\u201cWhen Vitamin C generates ROS, our drug can use it to become more accurate,\u201d Ali explained. Combining the pro-drug with Vitamin C allowed the researchers to use one-tenth of the dosage to achieve the same results as with the pro-drug alone.<\/p>\n\n\n\n

And the results were amazing.<\/p>\n\n\n\n

\u201cWe got phenomenal results in cell lines, multiple TNBC and even glioblastoma cell lines,\u201d said Ali. \u201cWe carried out some animal studies with three different TNBC models and in two of the models, tumors were completely diminished. Gone.\u201d<\/p>\n\n\n\n

Even weeks after treatment, Ali, said, the cancer did not return.<\/p>\n\n\n\n

Getting to market<\/strong><\/h2>\n\n\n\n
\"A
Taufeeque Ali (’24, PhD Chemistry & Biochemistry) is the CEO of SynXT Therapeutics, Inc.<\/figcaption><\/figure>\n\n\n\n

Encouraged by their promising results, Ali and Peng patented their work. In 2024, they began exploring how to bring their pro-drug to market. The pair attended the National Science Foundation\u2019s I-Corps program<\/a> at UWM and interviewed oncologists, scientists, founders, and cancer patients to determine if there was an audience for their product. In 2025, they founded SynXT Therapeutics, Inc., with Ali as the company\u2019s CEO and Peng as its Chief Scientific Officer.<\/p>\n\n\n\n

They are in the long process of getting ready to apply for clinical trials through the Food and Drug Administration. The drug must pass through all three phases of FDA clinical trials before it can be used for cancer treatments.<\/p>\n\n\n\n

Currently, Ali and Peng are conducting a small pilot study to test the drug\u2019s efficacy against patient-derived tumors. They\u2019ll increase the scale of the study and conduct further animal testing before they apply for an Investigational New Drug (IND) approval. The process will likely take years and will be expensive.<\/p>\n\n\n\n

But even if it\u2019s slow going, there\u2019s room for optimism: Ali said the pro-drug is promising in not only treating triple negative breast cancer, but has also shown signs of efficacy when they performed limited tests on glioblastomas and prostate cancers. For now, though, the team is concentrating on TNBC.<\/p>\n\n\n\n

And if the process gets to be overwhelming or frustrating, Peng remembers why she began doing the research in the first place.<\/p>\n\n\n\n

\u201cFor \u2018normal\u2019 breast cancer, we have very good hormone therapy, but 20% of breast cancer patients are triple negative. TNBC is very aggressive, so they really suffer from that,\u201d Peng said. \u201cThat\u2019s my goal, is to help these women.\u201d<\/p>\n\n\n\n

By Sarah Vickery, College of Letters & Science<\/em><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

Triple negative breast cancer (TNBC) is one of the most aggressive forms of breast cancer, and it does not respond to any of the hormone therapies designed to treat other types of breast cancer. Instead, the first line of defense …<\/p>\n","protected":false},"author":785,"featured_media":31393,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","uwm_wg_additional_authors":[]},"categories":[1648,1961,1954,1846],"tags":[1855],"class_list":["post-31392","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-in-focus","category-in-focus-2026","category-natural-sciences","category-research-news","tag-may"],"yoast_head":"\nLetters & Science<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/uwm.edu\/letters-science\/in-focus\/research-news\/chemistry-researchers-start-up-takes-aim-at-triple-negative-breast-cancer-without-chemo-side-effects\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Chemistry researchers\u2019 start-up takes aim at triple-negative breast cancer \u2013 without chemo side effects\" \/>\n<meta property=\"og:description\" content=\"Triple negative breast cancer (TNBC) is one of the most aggressive forms of breast cancer, and it does not respond to any of the hormone therapies designed to treat other types of breast cancer. Instead, the first line of defense …\" \/>\n<meta property=\"og:url\" content=\"https:\/\/uwm.edu\/letters-science\/in-focus\/research-news\/chemistry-researchers-start-up-takes-aim-at-triple-negative-breast-cancer-without-chemo-side-effects\/\" \/>\n<meta property=\"og:site_name\" content=\"Letters & Science\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-05T17:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-06T03:09:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/uwm.edu\/letters-science\/wp-content\/uploads\/sites\/255\/2026\/05\/Peng-and-student.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"720\" \/>\n\t<meta property=\"og:image:height\" content=\"480\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sarah E Vickery\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sarah E Vickery\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/uwm.edu\\\/letters-science\\\/in-focus\\\/research-news\\\/chemistry-researchers-start-up-takes-aim-at-triple-negative-breast-cancer-without-chemo-side-effects\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/uwm.edu\\\/letters-science\\\/in-focus\\\/research-news\\\/chemistry-researchers-start-up-takes-aim-at-triple-negative-breast-cancer-without-chemo-side-effects\\\/\"},\"author\":{\"name\":\"Sarah E Vickery\",\"@id\":\"https:\\\/\\\/uwm.edu\\\/letters-science\\\/#\\\/schema\\\/person\\\/79ba9316328e022fb78add26239f8453\"},\"headline\":\"Chemistry researchers\u2019 start-up takes aim at triple-negative breast cancer \u2013 without chemo side effects\",\"datePublished\":\"2026-05-05T17:00:00+00:00\",\"dateModified\":\"2026-05-06T03:09:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/uwm.edu\\\/letters-science\\\/in-focus\\\/research-news\\\/chemistry-researchers-start-up-takes-aim-at-triple-negative-breast-cancer-without-chemo-side-effects\\\/\"},\"wordCount\":799,\"image\":{\"@id\":\"https:\\\/\\\/uwm.edu\\\/letters-science\\\/in-focus\\\/research-news\\\/chemistry-researchers-start-up-takes-aim-at-triple-negative-breast-cancer-without-chemo-side-effects\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/uwm.edu\\\/letters-science\\\/wp-content\\\/uploads\\\/sites\\\/255\\\/2026\\\/05\\\/Peng-and-student.webp\",\"keywords\":[\"May\"],\"articleSection\":[\"In Focus\",\"In Focus 2026\",\"Natural Sciences\",\"Research News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/uwm.edu\\\/letters-science\\\/in-focus\\\/research-news\\\/chemistry-researchers-start-up-takes-aim-at-triple-negative-breast-cancer-without-chemo-side-effects\\\/\",\"url\":\"https:\\\/\\\/uwm.edu\\\/letters-science\\\/in-focus\\\/research-news\\\/chemistry-researchers-start-up-takes-aim-at-triple-negative-breast-cancer-without-chemo-side-effects\\\/\",\"name\":\"Chemistry researchers\u2019 start-up takes aim at triple-negative breast cancer \u2013 without chemo side effects - Letters & Science\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/uwm.edu\\\/letters-science\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/uwm.edu\\\/letters-science\\\/in-focus\\\/research-news\\\/chemistry-researchers-start-up-takes-aim-at-triple-negative-breast-cancer-without-chemo-side-effects\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/uwm.edu\\\/letters-science\\\/in-focus\\\/research-news\\\/chemistry-researchers-start-up-takes-aim-at-triple-negative-breast-cancer-without-chemo-side-effects\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/uwm.edu\\\/letters-science\\\/wp-content\\\/uploads\\\/sites\\\/255\\\/2026\\\/05\\\/Peng-and-student.webp\",\"datePublished\":\"2026-05-05T17:00:00+00:00\",\"dateModified\":\"2026-05-06T03:09:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/uwm.edu\\\/letters-science\\\/#\\\/schema\\\/person\\\/79ba9316328e022fb78add26239f8453\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/uwm.edu\\\/letters-science\\\/in-focus\\\/research-news\\\/chemistry-researchers-start-up-takes-aim-at-triple-negative-breast-cancer-without-chemo-side-effects\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/uwm.edu\\\/letters-science\\\/in-focus\\\/research-news\\\/chemistry-researchers-start-up-takes-aim-at-triple-negative-breast-cancer-without-chemo-side-effects\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/uwm.edu\\\/letters-science\\\/in-focus\\\/research-news\\\/chemistry-researchers-start-up-takes-aim-at-triple-negative-breast-cancer-without-chemo-side-effects\\\/#primaryimage\",\"url\":\"https:\\\/\\\/uwm.edu\\\/letters-science\\\/wp-content\\\/uploads\\\/sites\\\/255\\\/2026\\\/05\\\/Peng-and-student.webp\",\"contentUrl\":\"https:\\\/\\\/uwm.edu\\\/letters-science\\\/wp-content\\\/uploads\\\/sites\\\/255\\\/2026\\\/05\\\/Peng-and-student.webp\",\"width\":720,\"height\":480,\"caption\":\"Chemistry & Biochemistry Professor Xiaohua Peng (left) is shown here with a former student. Peng is the co-founder of a start up that is developing a drug to treat an aggressive form of breast cancer.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/uwm.edu\\\/letters-science\\\/in-focus\\\/research-news\\\/chemistry-researchers-start-up-takes-aim-at-triple-negative-breast-cancer-without-chemo-side-effects\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/uwm.edu\\\/letters-science\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"In Focus\",\"item\":\"https:\\\/\\\/uwm.edu\\\/letters-science\\\/in-focus\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Research News\",\"item\":\"https:\\\/\\\/uwm.edu\\\/letters-science\\\/in-focus\\\/research-news\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Chemistry researchers\u2019 start-up takes aim at triple-negative breast cancer \u2013 without chemo side effects\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/uwm.edu\\\/letters-science\\\/#website\",\"url\":\"https:\\\/\\\/uwm.edu\\\/letters-science\\\/\",\"name\":\"Letters & Science\",\"description\":\"College of\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/uwm.edu\\\/letters-science\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/uwm.edu\\\/letters-science\\\/#\\\/schema\\\/person\\\/79ba9316328e022fb78add26239f8453\",\"name\":\"Sarah E Vickery\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fdc2a8fd73cb2a506bc8cb0bf544eba2c6d61ac223cedb9612c0d7b103a86b28?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fdc2a8fd73cb2a506bc8cb0bf544eba2c6d61ac223cedb9612c0d7b103a86b28?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fdc2a8fd73cb2a506bc8cb0bf544eba2c6d61ac223cedb9612c0d7b103a86b28?s=96&d=mm&r=g\",\"caption\":\"Sarah E Vickery\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Letters & Science","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/uwm.edu\/letters-science\/in-focus\/research-news\/chemistry-researchers-start-up-takes-aim-at-triple-negative-breast-cancer-without-chemo-side-effects\/","og_locale":"en_US","og_type":"article","og_title":"Chemistry researchers\u2019 start-up takes aim at triple-negative breast cancer \u2013 without chemo side effects","og_description":"Triple negative breast cancer (TNBC) is one of the most aggressive forms of breast cancer, and it does not respond to any of the hormone therapies designed to treat other types of breast cancer. Instead, the first line of defense …","og_url":"https:\/\/uwm.edu\/letters-science\/in-focus\/research-news\/chemistry-researchers-start-up-takes-aim-at-triple-negative-breast-cancer-without-chemo-side-effects\/","og_site_name":"Letters & Science","article_published_time":"2026-05-05T17:00:00+00:00","article_modified_time":"2026-05-06T03:09:38+00:00","og_image":[{"width":720,"height":480,"url":"https:\/\/uwm.edu\/letters-science\/wp-content\/uploads\/sites\/255\/2026\/05\/Peng-and-student.webp","type":"image\/webp"}],"author":"Sarah E Vickery","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Sarah E Vickery","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/uwm.edu\/letters-science\/in-focus\/research-news\/chemistry-researchers-start-up-takes-aim-at-triple-negative-breast-cancer-without-chemo-side-effects\/#article","isPartOf":{"@id":"https:\/\/uwm.edu\/letters-science\/in-focus\/research-news\/chemistry-researchers-start-up-takes-aim-at-triple-negative-breast-cancer-without-chemo-side-effects\/"},"author":{"name":"Sarah E Vickery","@id":"https:\/\/uwm.edu\/letters-science\/#\/schema\/person\/79ba9316328e022fb78add26239f8453"},"headline":"Chemistry researchers\u2019 start-up takes aim at triple-negative breast cancer \u2013 without chemo side effects","datePublished":"2026-05-05T17:00:00+00:00","dateModified":"2026-05-06T03:09:38+00:00","mainEntityOfPage":{"@id":"https:\/\/uwm.edu\/letters-science\/in-focus\/research-news\/chemistry-researchers-start-up-takes-aim-at-triple-negative-breast-cancer-without-chemo-side-effects\/"},"wordCount":799,"image":{"@id":"https:\/\/uwm.edu\/letters-science\/in-focus\/research-news\/chemistry-researchers-start-up-takes-aim-at-triple-negative-breast-cancer-without-chemo-side-effects\/#primaryimage"},"thumbnailUrl":"https:\/\/uwm.edu\/letters-science\/wp-content\/uploads\/sites\/255\/2026\/05\/Peng-and-student.webp","keywords":["May"],"articleSection":["In Focus","In Focus 2026","Natural Sciences","Research News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/uwm.edu\/letters-science\/in-focus\/research-news\/chemistry-researchers-start-up-takes-aim-at-triple-negative-breast-cancer-without-chemo-side-effects\/","url":"https:\/\/uwm.edu\/letters-science\/in-focus\/research-news\/chemistry-researchers-start-up-takes-aim-at-triple-negative-breast-cancer-without-chemo-side-effects\/","name":"Chemistry researchers\u2019 start-up takes aim at triple-negative breast cancer \u2013 without chemo side effects - Letters & Science","isPartOf":{"@id":"https:\/\/uwm.edu\/letters-science\/#website"},"primaryImageOfPage":{"@id":"https:\/\/uwm.edu\/letters-science\/in-focus\/research-news\/chemistry-researchers-start-up-takes-aim-at-triple-negative-breast-cancer-without-chemo-side-effects\/#primaryimage"},"image":{"@id":"https:\/\/uwm.edu\/letters-science\/in-focus\/research-news\/chemistry-researchers-start-up-takes-aim-at-triple-negative-breast-cancer-without-chemo-side-effects\/#primaryimage"},"thumbnailUrl":"https:\/\/uwm.edu\/letters-science\/wp-content\/uploads\/sites\/255\/2026\/05\/Peng-and-student.webp","datePublished":"2026-05-05T17:00:00+00:00","dateModified":"2026-05-06T03:09:38+00:00","author":{"@id":"https:\/\/uwm.edu\/letters-science\/#\/schema\/person\/79ba9316328e022fb78add26239f8453"},"breadcrumb":{"@id":"https:\/\/uwm.edu\/letters-science\/in-focus\/research-news\/chemistry-researchers-start-up-takes-aim-at-triple-negative-breast-cancer-without-chemo-side-effects\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/uwm.edu\/letters-science\/in-focus\/research-news\/chemistry-researchers-start-up-takes-aim-at-triple-negative-breast-cancer-without-chemo-side-effects\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/uwm.edu\/letters-science\/in-focus\/research-news\/chemistry-researchers-start-up-takes-aim-at-triple-negative-breast-cancer-without-chemo-side-effects\/#primaryimage","url":"https:\/\/uwm.edu\/letters-science\/wp-content\/uploads\/sites\/255\/2026\/05\/Peng-and-student.webp","contentUrl":"https:\/\/uwm.edu\/letters-science\/wp-content\/uploads\/sites\/255\/2026\/05\/Peng-and-student.webp","width":720,"height":480,"caption":"Chemistry & Biochemistry Professor Xiaohua Peng (left) is shown here with a former student. Peng is the co-founder of a start up that is developing a drug to treat an aggressive form of breast cancer."},{"@type":"BreadcrumbList","@id":"https:\/\/uwm.edu\/letters-science\/in-focus\/research-news\/chemistry-researchers-start-up-takes-aim-at-triple-negative-breast-cancer-without-chemo-side-effects\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/uwm.edu\/letters-science\/"},{"@type":"ListItem","position":2,"name":"In Focus","item":"https:\/\/uwm.edu\/letters-science\/in-focus\/"},{"@type":"ListItem","position":3,"name":"Research News","item":"https:\/\/uwm.edu\/letters-science\/in-focus\/research-news\/"},{"@type":"ListItem","position":4,"name":"Chemistry researchers\u2019 start-up takes aim at triple-negative breast cancer \u2013 without chemo side effects"}]},{"@type":"WebSite","@id":"https:\/\/uwm.edu\/letters-science\/#website","url":"https:\/\/uwm.edu\/letters-science\/","name":"Letters & Science","description":"College of","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/uwm.edu\/letters-science\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/uwm.edu\/letters-science\/#\/schema\/person\/79ba9316328e022fb78add26239f8453","name":"Sarah E Vickery","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/fdc2a8fd73cb2a506bc8cb0bf544eba2c6d61ac223cedb9612c0d7b103a86b28?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/fdc2a8fd73cb2a506bc8cb0bf544eba2c6d61ac223cedb9612c0d7b103a86b28?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fdc2a8fd73cb2a506bc8cb0bf544eba2c6d61ac223cedb9612c0d7b103a86b28?s=96&d=mm&r=g","caption":"Sarah E Vickery"}}]}},"acf":[],"meta_fields":{"_edit_lock":["1778036987:785"],"_thumbnail_id":["31393"],"_edit_last":["785"],"feat_img_video":[""],"feat_img_gallery":[""],"feat_img_caption":["feat-img-caption-on"],"breadcrumbs_display":["breadcrumbs-on"],"otp_nav_display":["otp-on-mobile"],"post_layout":["post-layout-theme"],"_yoast_wpseo_primary_category":["1846"],"_yoast_wpseo_content_score":["30"],"_yoast_wpseo_focuskeywords":[""],"_yoast_wpseo_keywordsynonyms":[""],"_yoast_wpseo_estimated-reading-time-minutes":["5"],"_yoast_indexnow_last_ping":["1778036979"]},"publishpress_future_action":{"enabled":false,"date":"2026-05-17 05:33:50","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/uwm.edu\/letters-science\/wp-json\/wp\/v2\/posts\/31392","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/uwm.edu\/letters-science\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/uwm.edu\/letters-science\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/uwm.edu\/letters-science\/wp-json\/wp\/v2\/users\/785"}],"replies":[{"embeddable":true,"href":"https:\/\/uwm.edu\/letters-science\/wp-json\/wp\/v2\/comments?post=31392"}],"version-history":[{"count":2,"href":"https:\/\/uwm.edu\/letters-science\/wp-json\/wp\/v2\/posts\/31392\/revisions"}],"predecessor-version":[{"id":31455,"href":"https:\/\/uwm.edu\/letters-science\/wp-json\/wp\/v2\/posts\/31392\/revisions\/31455"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/uwm.edu\/letters-science\/wp-json\/wp\/v2\/media\/31393"}],"wp:attachment":[{"href":"https:\/\/uwm.edu\/letters-science\/wp-json\/wp\/v2\/media?parent=31392"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/uwm.edu\/letters-science\/wp-json\/wp\/v2\/categories?post=31392"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/uwm.edu\/letters-science\/wp-json\/wp\/v2\/tags?post=31392"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}